$2.2 Billion Johnson & Johnson Settlement Sends New Warning: Antipsychotic Drugs Should Not Be Used to Treat Dementia
Statement of California Advocates for Nursing Home Reform, Center for Medicare Advocacy, Legal Aid Justice Center, Long Term Care Community Coalition, and The National Consumer Voice for Quality Long-Term Care The Department of Justice’s $2.2 billion settlement with Johnson & Johnson over allegations that it illegally promoted Risperdal to treat symptoms of dementia sends a new warning to the pharmaceutical and long-term care industries that antipsychotic drugs are inappropriate and potentially dangerous when prescribed for the elderly.